Thin melanomas: predictive lethal characteristics from a 30-year clinical experience.

Department of Surgery, Duke University Medical Center Durham, North Carolina 27710, USA.
Annals of Surgery (Impact Factor: 7.19). 10/2003; 238(4):528-35; discussion 535-7.
Source: PubMed

ABSTRACT To guide treatment and clinical follow-up by defining the natural history of thin melanomas and identifying negative prognostic characteristics that may delineate high-risk patients.
In following > 10,000 patients with cutaneous melanoma over the past 30 years, our institution has observed nodal or metastatic disease in approximately 15% of patients with a thin (<1 mm) primary lesion.
A database query of patients with cutaneous melanoma returned 1158 patients with primary lesion < or = 1 mm thick and who received their initial treatment at a single institution. Median follow-up was 11 years (range, 1 to 34 years). Patient and melanoma characteristics as well as outcomes were recorded and statistically analyzed.
6.6% of patients had nodal or distant disease at presentation. Over time, an additional 9.4% developed metastases, including nodal and distal recurrences. Overall incidence of advanced disease was 15.3%. Univariate analysis identified male gender (P = 0.01), advanced age (>45 years; P = 0.05), and Breslow thickness (>0.75 mm; P = 0.008) as significant negative prognostic characteristics. Of patients with these 3 high-risk characteristics, 19.7% developed advanced disease (likelihood ratio 6.3; P = 0.007 versus nonhigh-risk patients). This group had more than twice the incidence of nodal recurrences. Patients with recurrence had significantly decreased 10-year survival (82% versus 45%; P < 0.0001). Surprisingly, neither ulceration nor Clark level predicted advanced disease.
Thin melanomas are potentially lethal lesions. Long-term follow-up identified a high-risk population of older males with tumors between 0.75 mm and 1.0 mm whose risk of recurrent disease approaches 20%. Traditionally accepted negative prognostic factors such as ulceration and discordant Clark levels are not predictive for metastasis in this population. Given the poor prognosis associated with recurrent disease, we recommend close clinical evaluation and follow-up to maximize accurate staging and therapeutic options.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Primäre Ziele der Nachsorge des malignen Melanoms der Haut sind die frühzeitige Diagnose von Zweitmelanomen und Tumorrezidiven. Die Früherkennung der Rezidive ist für die Patienten prognoserelevant. Durch ein strukturiertes stadienadaptiertes Nachsorgeschema werden mehr als 80% der Rezidive hauptsächlich in Nachsorgeuntersuchungen erkannt. Durch die körperliche Untersuchung werden die meisten Rezidive detektiert und durch die Lymphknotensonographie wird eine Früherkennung lokoregionärer Rezidive ermöglicht, bevor diese tastbar werden. Darüber hinaus sollten bildgebende Verfahren stadien- und risikoadaptiert eingesetzt werden, bei Melanomen im Primärtumorstadium sind diese verzichtbar. Somit kann bei diesen Melanomen (besonders bei Tumordicken ≤1,0mm) der Umfang der Untersuchungen im Vergleich zu bisherigen Empfehlungen deutlich reduziert werden. Dadurch können die Kosten für die Nachsorgeuntersuchungen erheblich verringert werden, ohne das Risiko für die Patienten deutlich zu erhöhen. Im Stadium III wird eine Intensivierung der Nachsorgeuntersuchungen durch bildgebende Verfahren zur Verbesserung der Früherkennung von Rezidiven empfohlen. The primary goal of follow-up examinations in cutaneous melanoma is to detect development of second melanomas or tumor recurrences in an early phase of development. Early detection of recurrences has prognostic impact for the patients. More than 80% of all recurrences are primarily detected during follow-up examinations when a structured stage-adapted schedule is applied. In the majority of cases, recurrences are detected by physical examinations. Lymph node ultrasound enables early detection of locoregional recurrences before they become palpable and represents a sensitive examination method. Further imaging techniques in primary tumors are dispensable. In primary melanomas and particularly in those with a tumor thickness of less than 1mm a reduction of the kind and frequency of technical examinations can be recommended according to recent publications. Hence the costs of follow-up examinations can be reduced clearly without increased risk for the patients. In stage III patients an intensified schedule including imaging techniques can help in increasing the early detection of recurrences. SchlüsselwörterNachsorge-Melanom-Lymphknotensonographie-Röntgendiagnostik-Blutuntersuchungen KeywordsMelanoma-Surveillance-Lymph node ultrasound-X-ray diagnostics-Blood tests
    Der Onkologe 12/2010; 16(12):1175-1181. DOI:10.1007/s00761-010-1930-7 · 0.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant melanoma is a disease with a continuously increasing incidence and an unfavorable outcome in stage IV. It is a tumor with intense metabolic activity that produces and releases in the blood stream enzymes, cytokines and growth factors. Although several proteins were suggested as serum markers in malignant melanoma, until now none has proven itself sensitive enough to be currently used in treatment monitoring and patient follow-up. The target of this paper is to synthesize the information from the literature referring to three of the most commonly used serum markers in malignant melanoma. With the exception of LDH, whose role is well established, MIA and S100B are still the subject of various studies. Malignant melanoma is a surprising disease, with a clinical evolution that cannot be patterned. It is hard to imagine that, although correctly excised, a tumor with a thickness of less than 1 mm cannot be cured. Nevertheless, 5–15% of these patients develop metastases (1, 2) and eventually die. On the other hand, a large number of thick, ulcerated melanomas never relapse (3). Because the evolution of malignant melanomas it is hard to predict, mostly in stages I and II, efforts are being made in order to identify markers that can correlate with disease progression and its response to treatment. Tumor markers are molecules produced either by the tumor cells or by the normal ones, as response to cancerous invasion (4). Many of the tumor markers are intracellular or extracellular proteins released into the body's fluids. The ideal tumor marker should be: specific to a precise cancer type, undetectable in healthy subjects or in subjects with benign pathology and sensitive enough to detect small, incipient tumors.
  • Source
    Journal of Clinical Oncology 10/2004; 22(18):3651-3. DOI:10.1200/JCO.2004.06.921 · 17.88 Impact Factor


Available from